Publication | Open Access
The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: The <scp>CANA‐HF</scp> study
69
Citations
22
References
2020
Year
In this small and short-term study of patients with T2DM and HFrEF, interrupted early after only 36 patients, canagliflozin did not improve the primary endpoints of peak VO<sub>2</sub> or VE/VCO<sub>2</sub> slope compared to sitagliptin, while showing favourable trends observed on several additional surrogate endpoints such as lean peak VO<sub>2</sub> , VAT and quality of life.
| Year | Citations | |
|---|---|---|
Page 1
Page 1